Compare MRAM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | CHRS |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 291.5M |
| IPO Year | 2016 | 2014 |
| Metric | MRAM | CHRS |
|---|---|---|
| Price | $9.41 | $1.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $14.00 | $5.51 |
| AVG Volume (30 Days) | 433.4K | ★ 1.3M |
| Earning Date | 03-04-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | N/A | ★ 1.43 |
| Revenue | ★ $49,417,000.00 | N/A |
| Revenue This Year | $10.87 | $88.67 |
| Revenue Next Year | $8.33 | $28.64 |
| P/E Ratio | ★ N/A | $1.11 |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $4.34 | $0.72 |
| 52 Week High | $17.24 | $2.62 |
| Indicator | MRAM | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 41.96 |
| Support Level | $8.42 | $1.55 |
| Resistance Level | $9.74 | $1.75 |
| Average True Range (ATR) | 0.58 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 28.25 | 14.11 |
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.